Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityActive in the last 2 years

Sophia Y. Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6772-8483; OpenAlex author ID A5077893987. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
33
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: 2 papers · 2024: 1 paper · 2025: 2 papers

Papers 9

  1. Distinct response to IL-1β blockade in liver- and lung-specific metastasis mouse models of pancreatic cancer with heterogeneous tumor microenvironments. Co-author DOI 10.1186/s40164-025-00607-w↗
  2. EphA2-targeted alpha-particle theranostics for enhancing PDAC treatment. Co-author DOI 10.7150/thno.106948↗
  3. Targeting heterogeneous tumor microenvironments in pancreatic cancer mouse models of metastasis by TGF-β depletion. Co-author DOI 10.1172/jci.insight.182766↗
  4. Engineered TCR T-cell therapy targeting mass spectrometry-identified natural epitope in PDAC. Co-author DOI 10.1016/j.canlet.2023.216366↗
  5. CLDN18.2 BiTE Engages Effector and Regulatory T Cells for Antitumor Immune Response in Preclinical Models of Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2023.06.037↗
  6. CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinoma. Co-author DOI 10.1084/jem.20211631↗
  7. Assessing the Financial Burden Associated With Treatment Options for Resectable Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000002069↗
  8. Impact of Angiotensin Receptor Blocker Use on Overall Survival Among Patients Undergoing Resection for Pancreatic Cancer. Co-author DOI 10.1007/s00268-017-4021-8↗
  9. Metformin Use Is Associated with Improved Survival in Patients Undergoing Resection for Pancreatic Cancer. Co-author DOI 10.1007/s11605-016-3173-4↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lei Zheng · 4 shared papers, 2022–2025 · strength 0.64
  2. Heng‐Chung Kung · 3 shared papers, 2023–2025 · strength 0.58
  3. Jianxin Wang · 3 shared papers, 2022–2024 · strength 0.47
  4. William R. Burns · 2 shared papers, 2024–2025 · strength 0.41
  5. Lei Zheng · 2 shared papers, 2024–2025 · strength 0.41
  6. Kenji Fujiwara · 2 shared papers, 2022–2023 · strength 0.28
  7. Marcelo Cerullo · 3 shared papers, 2016–2018 · strength 0.26
  8. Faiz Gani · 3 shared papers, 2016–2018 · strength 0.26
  9. Timothy Michael Pawlik · 3 shared papers, 2016–2018 · strength 0.26
  10. Nan Niu · 2 shared papers, 2022–2023 · strength 0.25
  11. Yao Xu · 2 shared papers, 2022–2023 · strength 0.25
  12. Kaiyi Mu · 1 shared paper, 2025 · strength 0.23
  13. Sridhar Nimmagadda · 1 shared paper, 2025 · strength 0.22
  14. Ajay Sharma · 1 shared paper, 2025 · strength 0.22
  15. Elizabeth M. Jaffee · 1 shared paper, 2025 · strength 0.22
  16. William L. Hwang · 1 shared paper, 2024 · strength 0.18
  17. Jun Yu · 1 shared paper, 2023 · strength 0.17
  18. Tengyi Zhang · 1 shared paper, 2023 · strength 0.17
  19. William Reece Burns · 1 shared paper, 2023 · strength 0.13
  20. Noelle R. Jurcak · 1 shared paper, 2023 · strength 0.13
  21. Junke Wang · 1 shared paper, 2023 · strength 0.13
  22. Pan Li · 1 shared paper, 2023 · strength 0.13
  23. Ding Ding · 1 shared paper, 2022 · strength 0.12
  24. Jin Peng He · 1 shared paper, 2022 · strength 0.12
  25. Brian T. Herbst · 1 shared paper, 2022 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.